Every 8-K that Absci Corporation (ABSI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ABSI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ABSI filings page.
Absci Corporation reported second-quarter 2026 results and pipeline updates. Revenue from partner programs was $0.3 million for the quarter ended June 30, 2026, compared with $0.6 million a year earlier. Research and development expenses rose to $22.6 million from $20.5 million, and selling, general, and administrative expenses increased to $9.2 million from $8.5 million. Net loss widened to $33.2 million from $30.6 million.
Cash, cash equivalents, and marketable securities were $201.1 million as of June 30, 2026, up from $125.7 million as of March 31, 2026, reflecting $93.6 million of net proceeds from a $100 million underwritten offering that included a $40 million strategic equity investment from Eli Lilly & Company. Absci now believes this cash position will fund operating plans into the second half of 2028.
Absci highlighted positive interim Phase 1 data from the HEADLINE trial of ABS-201 for pattern hair loss, with blinded data suggesting the drug was well tolerated and an estimated half-life of at least 65 days, supporting potential dosing two or three times over six months. The company anticipates interim proof-of-concept data for pattern hair loss in the second half of 2026, full proof-of-concept data in early 2027, and initiation of a Phase 2 trial of ABS-201 for endometriosis in the fourth quarter of 2026.
Absci Corporation has priced an underwritten public offering of 13,495,277 shares of its common stock. The shares are being sold at $7.41 per share, for expected gross proceeds of about $100 million and estimated net proceeds of approximately $93.5 million after fees and expenses.
All shares are being sold by Absci under an effective shelf registration statement on Form S-3. The company plans to use the net proceeds primarily to advance ABS-201, its AI-designed anti-PRLR antibody program for androgenetic alopecia and endometriosis, and for working capital and general corporate purposes.
Absci Corporation reported positive interim Phase 1 results for ABS-201 from its HEADLINE trial in healthy adults with and without androgenetic alopecia. In four single ascending dose cohorts totaling 32 participants, intravenous ABS-201 at 150, 450, 900, and 1800 mg appeared well tolerated with no serious adverse events reported.
Most treatment-emergent adverse events were mild; one moderate headache was assessed as unlikely related to treatment. Interim pharmacokinetic data indicate an estimated half-life of at least 65 days, supporting a potential dosing schedule of two or three injections over six months. The study has advanced into a subcutaneous multiple ascending dose phase in androgenetic alopecia participants, with interim proof-of-concept data expected in the second half of 2026 and full proof-of-concept data in early 2027.
Absci Corporation reported the results of its Annual Meeting of Stockholders held on June 4, 2026. As of the April 7, 2026 record date, 155,447,428 common shares were outstanding and entitled to vote.
Stockholders elected Class II directors Prof Sir Menelas Pangalos, Ph.D. (74,118,258 votes for, 9,332,380 withheld, 29,904,399 broker non-votes) and Daniel Rabinovitsj (69,590,534 votes for, 13,860,104 withheld, 29,904,399 broker non-votes) to serve until the 2029 annual meeting. They also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 111,058,992 votes for, 2,198,390 against, and 97,655 abstentions. No other matters were submitted to stockholders.
Absci Corporation reported first quarter 2026 financial and operating results and highlighted progress in its ABS-201 prolactin receptor programs. Revenue was $0.2 million for the quarter, down from $1.2 million a year earlier, while net loss widened to $29.6 million from $26.3 million.
Research and development expenses rose to $19.3 million, mainly to advance ABS-201 and other internal programs, while selling, general, and administrative costs eased slightly to $9.1 million. Cash, cash equivalents, and marketable securities totaled $125.7 million as of March 31, 2026, which the company believes will fund operations into the first half of 2028.
Clinically, Absci completed all four single-ascending-dose cohorts and began dosing the first multiple-ascending-dose cohort in its Phase 1/2a HEADLINE trial of ABS-201 for androgenetic alopecia, with preliminary safety, tolerability, and pharmacokinetic data expected in the second quarter of 2026. The company also introduced ABS-202, an anti-PRLR antibody for an undisclosed inflammation and immunology indication, and outlined plans to initiate a Phase 2 study of ABS-201 in endometriosis in the fourth quarter of 2026.
Absci Corporation reported 2025 results showing a widening loss as it invested heavily in its AI-driven drug pipeline while advancing lead program ABS-201. Revenue was $2.8 million for 2025, down from $4.5 million in 2024, reflecting lower partner program revenue.
Research and development expenses rose to $81.4 million from $63.9 million, driving a full-year net loss of $115.2 million versus $103.1 million a year earlier. Fourth-quarter net loss was $29.6 million. A $5.1 million gain from settling contingent consideration added $8.7 million of unrestricted cash.
The company highlighted clinical progress for ABS-201 in androgenetic alopecia, having dosed the first three cohorts in the Phase 1/2a HEADLINE trial with favorable emerging safety data and human ex vivo hair-growth findings. It also plans a Phase 2 trial of ABS-201 in endometriosis in the fourth quarter of 2026 and continues partnering efforts around ABS-101 and other AI-designed antibodies.
Cash, cash equivalents, and marketable securities totaled $144.3 million as of December 31, 2025, compared with $152.5 million as of September 30, 2025. Absci believes this liquidity will fund operations into the first half of 2028, supporting its multi-program clinical and discovery agenda.
Absci Corporation updated its governance and leadership structure. The board approved amended and restated indemnification agreements for all current directors and officers, adding more detailed change-in-control definitions, a presumption of good faith for officer indemnitees, coverage for separate counsel after a change in control, and an exclusion for incentive- and equity-based compensation subject to Rule 10D-1 clawbacks.
Chief Innovation Officer Andreas Busch, Ph.D. will retire effective March 31, 2026, then serve as a scientific advisor for two years starting April 3, 2026. Under an Advisor Agreement, he will receive a $25,500 annual cash retainer and equity awards of stock options for 22,800 shares and 5,800 restricted stock units. The company extended the exercise period on 2,489,290 vested stock options he holds, generally until three months after his advisory service ends or their original expiration, with specific provisions for cause, death, or disability; all unvested options at retirement will lapse.
Absci also announced the appointment of Ransi Somaratne, M.D., a veteran clinical development leader, as Chief Medical Officer to lead clinical strategy for its AI-designed therapeutics pipeline, including the ABS-201 program.
Absci Corporation reported that it will present a business update at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company has prepared a slide presentation for this event and made it part of its official disclosures.
The slides from Absci's conference presentation are filed as Exhibit 99.1 and are also available on the investor relations section of its website under “Events and Presentations.” This gives investors and analysts access to the same materials being shown at the healthcare conference.
Absci Corporation announced its financial results for the third quarter ended September 30, 2025. The company furnished a press release as Exhibit 99.1 under Item 2.02, and noted that this information is being furnished and not deemed filed under the Exchange Act.
Absci also filed a Fall 2025 corporate presentation as Exhibit 99.2, which includes internal pipeline program updates and is available in the News & Events section of its website.
Absci Corporation entered into a Letter Agreement with SBGH, LLC that amends the 2021 Totient merger terms and sets a final distribution of milestone consideration. The agreement provides that certain former Totient stockholders will receive approximately $7.6 million, and Absci will receive approximately $8.7 million, in full satisfaction of all potential milestone payments under the merger agreement.
The Letter Agreement, dated October 31, 2025, is filed as an exhibit, with certain portions redacted as immaterial and confidential.
Absci Corporation filed Amendment No. 1 to its Current Report to correct a clerical error in the Original Form 8-K. The amendment fixes an incorrect reference to the press release date, changing it from June 12, 2025 to August 12, 2025, and corrects coding for Item 9.01. On August 12, 2025 the company furnished a press release announcing results for the quarter ended June 30, 2025 (Exhibit 99.1) and a corporate presentation with internal pipeline updates (Exhibit 99.2). The furnished materials are stated as "furnished" and not "filed."
On August 12, 2025, Absci Corporation announced that it is reporting its financial results for the second quarter ended June 30, 2025 and furnished a press release as Exhibit 99.1. The filing states the press release and related information are being furnished rather than filed for purposes of Section 18 of the Exchange Act. On the same date the company released and made available a corporate presentation containing certain internal pipeline program updates, which is filed as Exhibit 99.2 and posted in the "News & Events" section of the company website. This Form 8-K notifies investors of the availability of the press release and presentation, but it does not include the underlying financial figures or detailed results within the body of the filing.